Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus–related hepatocellular carcinoma after radiofrequency ablation
Teng‐Yu Lee, Jaw‐Town Lin, Yi‐Siou Zeng, Yi‐Ju Chen, Ming‐Shiang Wu, Chun‐Ying Wu – 1 October 2015 – Radiofrequency ablation (RFA) is the best choice for curative treatment of hepatocellular carcinoma (HCC) cases not suitable for surgical intervention, but efforts should be made to reduce the risk of tumor recurrence. We aimed to investigate the association between nucleos(t)ide analog (NA) therapy for hepatitis B virus (HBV) and the risk of HCC recurrence post‐RFA.